Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Key Highlights
- ➤BioAge (BIOA) and Deep Origin launch multi-target AI drug-discovery collaboration
- ➤Deep Origin delivers multiple structurally distinct hits against BioAge’s first target in under three months
- ➤BioAge validates Deep Origin’s computationally identified hits in its wet lab
- ➤BioAge advances the first target into hit-to-lead optimization
- ➤Deep Origin is eligible for success-based milestone payments
Expert Statements
Michael Antonov, Co-founder and chief executive officer of Deep Origin
“BioAge finds its targets in human data, from people followed for decades, and many are novel targets with little known chemistry”
Michael Antonov, Co-founder and chief executive officer of Deep Origin
“This is exactly the problem our virtual screening was built to solve.”
Michael Antonov, Co-founder and chief executive officer of Deep Origin
“BioAge set a high bar for what its chemists would take forward, and the molecules that we delivered give BioAge's chemists strong starting points for optimization and position BioAge to move quickly through preclinical stages into the clinic.”
Kristen Fortney, Co-founder and chief executive officer of BioAge
“We believe AI can help shorten the path from human biology to new medicines, and this collaboration demonstrated its potential to accelerate early small molecule drug discovery”
Kristen Fortney, Co-founder and chief executive officer of BioAge
“Deep Origin's platform delivered high-quality chemical matter against a novel target in just months.”
Kristen Fortney, Co-founder and chief executive officer of BioAge
“We're thrilled with what we've accomplished together so far and look forward to extending the work to additional targets.”
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The collaboration has reached its first milestone: novel small-molecule hits identified computationally by Deep Origin against a novel BioAge target have been validated in BioAge’s wet lab.
The collaboration aims to speed drug development against novel targets by utilizing hybrid AI and physics-based models for computational drug discovery. Under the agreement, Deep Origin applies its computational drug discovery platform to BioAge’s selected targets to find novel hits against them. BioAge then verifies the functional activity of those hits in its own laboratory and leads hit-to-lead optimization, selection of development candidates, and clinical development. Deep Origin is eligible to receive success-based milestone payments.
Get started
Create a free account to read the full story.